The Cancer Immunotherapy Consortium (CIC) contributes to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
Publications prior to 2010 are credited to the Cancer Vaccine Consortium, the former name of the Cancer Immunotherapy Consortium.
A browser plugin may be required for the PDF file found this page.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for cancer patients.
Scientists tackled novel immunotherapy strategies that could potentially enable more patients with more types of cancer to benefit.